A Cross-sectional Study of Ocular Manifestations During the Covid-19 Pandemic in Hubei Province

NCT06355128 | Active Not Recruiting

• 1 other identifier: 20240307
• Study Type: observational
• Target: 16,000
• Locations: 1 country
• Sites: 1

Brief Summary

To investigate the clinical features of ocular manifestations during the novel coronavirus pneumonia pandemic in Hubei at the end of 2022

Conditions

COVID-19; Ocular Surface Disease

Outcome Measures

Primary Outcomes (1)

• Questionnaire data were collected and statistically analyzed.

  Information on demographic characteristics, COVID-19 pathogen test results, Covid-19 related systemic symptoms, ocular symptoms and eye discomfort medication was collected from questionnaires during the pandemic period (Phase A: December 7, 2022 to January 6, 2023, 1968 patients). Electronic medical records in the ophthalmic outpatient department of Zhongnan Hospital of Wuhan University and its medical union hospital- Qichun County People's Hospital were extracted during the pandemic period (Phase A) and the prevention and control periods (Phase B: November 7, 2022 to December 6, 2022 and Phase C: December 7, 2021 to January 6, 2022). The demographic, epidemiological, and clinical information of patients were compared.

  1/4/2024-30/4/2024

Study Arms (3)

the pandemic period (Phase A)

the pandemic period (Phase A)

Other: NOT

the prevention and control periods (Phase B: November 7, 2022 to December 6, 2022 ).

the prevention and control periods (Phase B: November 7, 2022 to December 6, 2022 and Phase C: December 7, 2021 to January 6, 2022).

Other: NOT

the prevention and control periods (Phase C: December 7, 2021 to January 6, 2022).

the prevention and control periods (Phase B: November 7, 2022 to December 6, 2022 and Phase C: December 7, 2021 to January 6, 2022).

Other: NOT

Interventions

NOT OTHER

NOT

the pandemic period (Phase A); the prevention and control periods (Phase B: November 7, 2022 to December 6, 2022 ).; the prevention and control periods (Phase C: December 7, 2021 to January 6, 2022).

Eligibility Criteria

• Sex: all
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

People from Hubei Province, China

You may qualify if:

• \. 2022.12.7 to 2023.2.6 People surveyed by wechat Questionnaire Star 2. 2021.12.7 to 2022.1.6 and 2022.11.7 to 2023.1.6 Patients who received ophthalmology treatment in Zhongnan Hospital of Wuhan University and Qichun People's Hospital

You may not qualify if:

• \. currently hospitalized patients. 2. severe patients. 3. Incomplete information. 4. cannot be contacted by telephone. 5. Refuse questionnaire survey. 6.The electronic medical record information is incomplete. 7. Those who do not go to the ophthalmic clinic after registration. 8.severe patients. 9. Cannot be contacted by phone.

Sponsors & Collaborators

• Zhongnan Hospital: lead
• Qichun People's Hospital: collaborator

Study Sites (1)

Zhongnan Hospital of Wuhan University

Wuhan, Hubei, 430071, China

Location

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Target Duration: 1 Month
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Director of Ophthalmology

Study Record Dates

• First Submitted: March 21, 2024
• First Posted: April 9, 2024
• Study Start: January 1, 2024
• Primary Completion: February 18, 2024
• Study Completion: April 30, 2024
• Last Updated: April 9, 2024

Record last verified: 2024-04

Locations

CN (1)